ABT · News · 20261102N

Amulet 360 Product Development

ABBOTT LABORATORIES · 2026-11-02 · Importance 26 · Surprise 24

Abbott’s investigational Amulet 360 Left Atrial Appendage Occluder showed 96.3% complete closure with zero-millimeter leak in the pivotal VERITAS study. More than 98% of study patients remained free of stroke of the most common kind or blood-clot complications through one year. The device targets people with non-valvular atrial fibrillation and could offer an alternative to long-term blood-thinning medication, particularly for patients who cannot tolerate it.

Key facts

• Abbott’s investigational Amulet 360 device showed 96.3% complete LAA closure and over 98% freedom from stroke or systemic embolism through one year in the VERITAS study. source
• Abbott’s investigational Amulet 360 achieved complete closure with zero-millimeter leak in 96.3% of patients evaluated by transesophageal echocardiography in the pivotal VERITAS study. source